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Background 
Quinine has been used since the 1930s to treat idiopathic muscular cramps. However, in 2006, 
because of efficacy and safety issues, the U.S. Food and Drug Administration cautioned about 
this off-label use of quinine, citing “665 reports of adverse events with serious outcomes (…), 
including 93 deaths”.1 Despite warnings, quinine is still prescribed to individuals with 
idiopathic muscular cramps. Further, many drinks such as bitter lemon or tonic waters contain 
quinine, and hence, many are exposed to quinine daily. This study explored the association 
between long-term quinine exposure and all-cause mortality. 
 
Methods  
This study used data recorded in The Health Improvement Network (THIN), a UK primary 
care database containing anonymized data on more than 12 million individuals representative 
of the UK population.2 Adults who received incident quinine sulfate/bisulfate/dihydrochloride 
prescriptions for idiopathic muscular cramps or restless leg syndrome for at least one year 
from January 1990 to December 2014 (last follow-up December 2015) at a mean dosage ≥100 
mg/day were considered to be exposed. The ‘start date’ (i.e., start of at-risk period) was 
defined as the first day of the first prescription of quinine. Individuals with muscular cramps 
or restless leg syndrome, never exposed to quinine or its derivatives, and with at least one 
year follow-up after a randomly selected ‘start date’ were eligible to be included in the 
unexposed sample. Three unexposed individuals were selected for every exposed individual. 
The samples were stratified in term of sex and age. Groups’ characteristics were compared 
using the Chi2 test or the Wilcoxon rank-sum test. The primary outcome (i.e., all-cause 
mortality) was compared between the exposed and the unexposed populations using Cox 
proportional hazards models adjusted on socio-demographic data, underlying conditions and 
concomitant prescriptions. Post-hoc subgroup analyses were conducted according to age and 
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to amount of exposure. The proportional hazards assumption for Cox models was checked 
graphically using the Schoenfeld residuals. All analyses were done using Stata 14.0. A two-
sided p-value ≤0.05 denoted statistical significance. The scheme for THIN to obtain and 
provide anonymous patient data was approved by a national ethic Committee in 2002. The 
need for informed consent was waived.  
 
Results  
The study population was made of 175,195 individuals (median age (IQR): 70 (61-78) years, 
women: 57.8%, median follow-up: 5.7 (3.1-8.9) years) (Table 1). There were 11,598 deaths 
(4.2 per 100 person-years) among the 44,699 exposed individuals versus 26,753 (3.2 per 100 
person-years) among the 130,496 unexposed individuals (adjusted HR: 1.24 (95%CI, 1.21-
1.27)). The increase in the risk of death was more pronounced in those under 50 years of age 
(adjusted HR: 3.06 (2.51-3.73)), whatever the indication for prescription (Table 2). A dose-
effect was found (adjusted HRs: 1.25 (1.20-1.30), 1.83 (1.72-1.94), and 2.24 (1.95-2.58), 
respectively for exposure 200-299, 300-399 and ≥400 mg/day by comparison to <200 mg/day, 
p-value for trend <0.001). 
 
Discussion 
Quinine compared to placebo is effective in reducing both cramps number and intensity.3 
Individuals included in this study received on average more than 100 mg/day of quinine, 
equivalent to a daily consumption of one liter of bitter lemon or tonic waters. 4  
Short term quinine exposure may lead to life threatening adverse events such as 
thrombocytopenia, hypoglycemia, or cardiac arrhythmia.3 In a recent study, the incidence rate 
ratio of death in individuals with heart failure initiating quinine for leg cramps was 1.19 (1.14-
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1.24) when compared to unexposed patients.5 Mortality of long-term users was not compared 
to mortality of short-term users.5  
The findings have limitations. Cramps may be due to underlying conditions or unmeasured 
confounders that predispose patients to higher mortality rather than exposure to quinine per 
se. No data was available regarding quinine beverages consumption. A competing risk may 
explain the lower increase of risk in the elderly but as death certificates were not accessible 
the mortality causes are unknown.  
Quinidine, an isomer of quinine increases by three-fold the risk of deaths by comparison to 
placebo or no treatment.6 These deaths are mainly explained by sudden cardiac arrests.6  
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Table 1: Characteristics of the study population 
 Exposed 
(n=44,699) 
Unexposed 
(n=130,496) 
p-value 
Age, median [IQR], years  71 (61-78) 70 (61-78) <0.001 
Female, n (%)   25,818 (57.8) 75,379 (57.8) 0.98 
‘Start date’, median [IQR] Jul 2006 (Feb 2003-Sept 2009) Jul 2006  (Apr 2003-Oct 2009) <0.001 
Duration of follow-up after ‘start date’, median [IQR], 
years  
 5.5 (3.0-8.7)  5.7 (3.1-8.9) <0.001 
Time between end of exposure and end of follow-up, , 
median [IQR], days 
25 (0-310) - - 
Quinine dosage, median [IQR], mg/day 203 (163-252) - - 
Underlying diseases, n (%)    0.04 
  Idiopathic muscular cramps 42,865 (95.9) 125,424 (96.1) 
  Restless leg syndrome 1,834 (4.1) 5,072 (3.9) 
Smoking status, n (%)    <0.001 
  Non-smokers  18,597 (41.6) 64,707 (49.6) 
  Ex-smokers 16,622 (37.2) 41,636 (31.9) 
  Smokers 7,814 (17.5) 20,214 (15.5) 
  Missing 1,666 (3.7) 3,939 (3.0) 
BMI, median [IQR], kg/m2 27.6 (24.2-31.6) 26.9 (24.0-30.4) <0.001 
Past history of, n (%)          
  Cancer 5,976 (13.4) 16,984 (13.0) 0.06 
  Hematological malignancy 593 (1.3) 1,069 (0.8) <0.001 
  Hypertension 19,748 (44.2) 53,046 (40.7) <0.001 
  Diabetes 8,522 (19.1) 15,645 (12.0) <0.001 
  Coronary artery disease 9,199 (20.6) 21,424 (16.4) <0.001 
  Congestive heart failure 2,610 (5.8) 5,696 (4.4) <0.001 
  Peripheral ischemic vascular disease 2,351 (5.3) 5,766 (4.4) <0.001 
  Cardiac conduction disorder 239 (0.5) 958 (0.7) 0.60 
  Cardiac dysrythmia 3,309 (7.4) 11,242 (8.6) <0.001 
  Amyotrophic lateral sclerosis 64 (0.1) 18 (0.01) <0.001 
  Multiple sclerosis 207 (0.5) 753 (0.6) 0.005 
  Muscular dystrophya 13 (0.03) 17 (0.01) 0.03 
Number of prescriptions of, n (%)    
  Diuretics b 0 (0-27) 0 (0-25) <0.001 
  Beta blockers b 0 (0-18) 0 (0-18) <0.001 
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  Calcium channel blockers  0 (0-17) 0 (0-15) <0.001 
  Including diltiazem c 0 (0-2) 0 (0-1) <0.001 
  B complex vitamin c 0 (0-0) 0 (0-0) <0.001 
  Statins b 0 (0-16)  0 (0-13) <0.001 
  Oral glucocorticoids b  0 (0-2) 0 (0-1) <0.001 
  Non steroidal anti-inflammatory drugs 0 (0-15) 0 (0-9) <0.001 
 
Continuous variables are reported as medians and interquartile ranges except for medication prescriptions which are reported as medians and 5%-95% ranges 
a including Steinert’s disease, nemaline body disease, Becker muscular dystrophy 
b can induce idiopathic muscular cramps 
c recommended for idiopathic muscular cramp treatment 
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Table 2: All-cause deaths in the exposed and unexposed populations 
 Exposed 
N (%) 
Unexposed 
N (%) 
Crude Hazard 
Ratios (95% CI) 
Adjusted Hazard 
Ratios 
(95% CI) 
Overall population     
All individuals      
  n 44,699 130,496   
  Deaths, n (%) 11,598 (26.0) 26,753 (20.5) 1.32 (1.29-1.35) 1.24 (1.21-1.27) 
Individuals aged ≤ 50 y     
  n 3,361 10,374   
  Deaths, n (%) 258 (7.7) 198 (1.9) 4.16 (3.46-5.01) 3.06 (2.51-3.73) 
Individual aged 51-70 y     
  n 18,935 56,280   
  Deaths, n (%) 3,069 (16.2) 5,957 (10.6) 1.60 (1.53-1.67) 1.37 (1.31-1.43) 
Individuals aged > 70 y     
  n 22,403 63,842   
  Deaths, n (%) 8,271 (36.9) 20,598 (32.3) 1.20 (1.17-1.23) 1.16 (1.13-1.19) 
Individuals with muscular cramps      
  All individuals      
  n 42,865 125,424   
  Deaths, n (%) 11,138 (26.0) 25,810 (20.6) 1.32 (1.29-1.35) 1.24 (1.21-1.27) 
Individuals aged ≤ 50 y     
  n 3,156 9,759   
  Deaths, n (%) 248 (7.9) 188 (1.9) 4.23 (3.50-5.12) 3.06 (2.50-3.76) 
Individuals aged 51-70 y     
  n 18,186 54,109   
  Deaths, n (%) 2,952 (16.2) 5,750 (10.6) 1.60 (1.53-1.67) 1.36 (1.30-1.42) 
Individuals aged > 70 y      
  n 21,523 61,556   
  Deaths, n (%) 7,938 (36.9) 19,872 (32.3) 1.20 (1.17-1.23) 1.16 (1.13-1.19) 
Individuals with restless leg syndrome     
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  All individuals      
  n 1,834 5,072   
  Deaths, n (%) 460 (25.1) 943 (18.6) 1.35 (1.21-1.51) 1.22 (1.09-1.36) 
Individuals aged ≤ 50 y     
  n 205 615   
  Deaths, n (%) 10 (4.9) 10 (1.6) 2.95 (1.22-7.08) 2.82 (1.17-6.81)a 
Individuals aged 51-70 y     
  n 749 2,171   
  Deaths, n (%) 117 (15.6) 207 (9.5) 1.64 (1.31-2.06) 1.54 (1.22-1.95) 
Individuals aged > 70 y     
  n 880 2,286   
  Deaths, n (%) 333 (37.8) 726 (31.8) 1.19 (1.05-1.36) 1.11 (1.02-1.21) 
 
All adjusted models were adjusted on age and sex. All the following variables were further considered to be included in the Cox multivariable models: BMI (<18, 18-24.9, 25-
29.9, ≥ 30 kg/m2), Townsend deprivation score (categorical), smoking status (non smoker, ex-smoker, smoker, missing), history of cancer (yes/no), hematological malignancy 
(yes/no), diabetes (yes/no), hypertension (yes/no), coronary artery disease (yes/no), congestive heart failure (yes/no), peripheral ischemic vascular disease (yes/no), cardiac 
conduction disorders (yes/no), cardiac dysrythmias (yes/no), amyotrophic lateral sclerosis (yes/no), multiple sclerosis (yes/no), or muscular dystrophies (yes/no), number of 
prescriptions of diuretics, beta blockers, calcium channel blockers (including diltiazem), oral glucocorticoids, and oral non-steroidal anti-inflammatory drugs (continuous or 
categorical depending of the log likelihood ratio test results). Some first-order interaction terms (e.g., interactions between group and sex, coronary artery disease and 
congestive heart failure, coronary artery disease and peripheral ischemic vascular disease) were also considered to be included in the models. Variables to be kept in the 
models were selected using manually stepwise procedures with backward selection. The final models were selected as those that provided the lowest Akaike information 
criterion and Bayesian information criterion. 
All HRs were statistically significant (all p-values <0.001except for adjusted HR regarding those >70 year-old with restless leg syndrome p-value=0.02). 
a Adjusted on age and sex only  
